International Journal of Women's Health and Reproduction Sciences

Home Aim and Scope Instructions to Authors Editorial Policies Editorial Board Authorship Agreement Form Open Access and Copyright

Jul 2024, Vol 12, Issue 3

CURRENT ISSUE ARCHIVE AHEAD OF PRINT / ACCEPTED ARTICLE MOST VIEWED ARTICLES NEWS RELATED LINKS

Advanced Search

For Author's & Reviewer's

Committee on Publication
Ethics (COPE) Flowchart

Recommendations for the Conduct

COPE: Reviewers

World Association of Medical Editors(WAME)

EQUATOR Resources : Reviewers

Poll

How do you find the scientific quality of the published articles on our web site?

Very good

Good

Fair

Bad

Very bad

Original Article
The Result of Cisplatin-Based Neoadjuvant Chemotherapy in Patients Diagnosed With Non-squamous Cell Carcinoma of the Cervix in Stage IB2 to IIB: A Retrospective Cohort Study
Azamosadat Mousavi¹, Malihe Azadehrah², Mitra Modarres-Gilani¹, Setareh Akhavan¹, Shahrzad Sheikh-Hasani¹, Mahboobeh Azadehrah²
¹Department of Gynecology Oncology, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran ²Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran
DOI: 10.15296/ijwhr.2023.33 Viewed : 1608 times Downloaded : 967 times. Keywords : Chemotherapy, Neoadjuvant, Cisplatin, Taxol, Cervical carcinoma, IB2-IIB
Full Text(PDF) \| Related Articles
Abstract

Objectives: Neoadjuvant chemotherapy is one of the most important and prevalent therapeutic strategies to reduce complications and mortality in patients with cervical carcinoma. Due to the higher pathologic prevalence of squamous cell carcinoma (SCC) than non-SCC of the cervix, effective therapeutic strategies have been mostly proposed in relation to the pathology of cervical SCC and, therefore, there is insufficient evidence suggesting treatment recommendations on the pathology of non-SCC of the cervix. Thus, this study aimed to investigate the outcome of cisplatin-based neoadjuvant chemotherapy with Taxol in patients diagnosed with non-SCC of the cervix in stage IB2-IIB. Materials and Methods: This study was a retrospective cohort study conducted on patients with non-SCC of the cervix. Patients treated with cisplatin-based neoadjuvant chemotherapy + paclitaxel were evaluated for the results and outcomes of neoadjuvant chemotherapy based on the inclusion criteria. Data were statistically analyzed using SPSS software as well as performing Kaplan-Meier procedure and the log-rank test. Results: The mean age of the studied cases was 44.9. Tumor size after neoadjuvant chemotherapy was less than 4 cm in six cases. Tumor spread to the inner and outer half of the stroma was observed in most cases. Tumor spread to the lymph node section was observed in seven cases. Three cases showed parametric involvement, and eight cases showed pelvic lymph node involvement. Complete response to treatment was recorded in two cases (16.7%), partial response was found in six cases (50%), and stable disease was seen in one case (21.7%). The average time of disease-free survival and progression-free survival in patients was 77 months, which demonstrated no significant difference (P = 0.30). Conclusions: Neoadjuvant chemotherapy in cases of non-SCC of the cervix as well as SCC of the cervix produced a strong anti-tumor and inhibitory effect in our study.